Company Overview
Snapshot
Founded in November 2020 by Assaf Bivas, ODE Pharma is a biotechnology company with 1–10 employees. The company has raised $1.5 million across one funding round. In November 2024, ODE Pharma secured seed funding from Pollen Group Israel.
Business overview
ODE Pharma is a pioneering biotechnology company focused on developing innovative treatments for respiratory and pulmonary disorders. The company leverages the body’s natural systems, specifically the gut microbiome and mitochondria, to advance healthcare and improve patient outcomes. Its core product, ODE-001, is currently in clinical trial and aims to enable cell restoration and regeneration, strengthen cells, and reduce inflammation, with potential applications in multiple respiratory and gastrointestinal diseases. ODE Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting the healthcare and pharmaceutical industries.
Strategic signal
In August 2024, ODE Pharma gained media attention for its research into the potential of papaya to treat cystic fibrosis in children. This highlights the company's innovative approach to leveraging natural compounds for therapeutic development and signals a potential expansion of its pipeline beyond its primary focus on respiratory and gastrointestinal diseases, attracting interest from the broader biotechnology and pediatric health sectors.
Log in to access full profile ›Company Intelligence Q&A
- What is ODE Pharma's primary focus?
- ODE Pharma is a biotechnology company focused on developing innovative treatments for respiratory and pulmonary disorders by harnessing the body’s natural systems, including the gut microbiome and mitochondria.
- When was ODE Pharma founded and by whom?
- ODE Pharma was founded in November 2020 by Assaf Bivas.
- What is the name of ODE Pharma's lead product?
- ODE Pharma's lead product is ODE-001, which is currently in clinical trial and aims to enable cell restoration and regeneration, strengthen cells, and reduce inflammation.
- What was a significant funding event for ODE Pharma?
- In November 2024, ODE Pharma secured seed funding totaling $1.5 million from Pollen Group Israel. This event marked a significant milestone for the company's development.
- What recent news highlighted ODE Pharma's research?
- In August 2024, news reported on ODE Pharma's exploration into the potential of papaya for treating cystic fibrosis in children, showcasing its innovative research directions.